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Microfluidic platform combining 
droplets and magnetic tweezers: 
application to HER2 expression in 
cancer diagnosis
Davide Ferraro1, Jérôme Champ2, Bruno Teste1, Marco Serra1, Laurent Malaquin3,  
Jean-Louis Viovy1, Patricia de Cremoux2 & Stephanie Descroix1
The development of precision medicine, together with the multiplication of targeted therapies 
and associated molecular biomarkers, call for major progress in genetic analysis methods, allowing 
increased multiplexing and the implementation of more complex decision trees, without cost 
increase or loss of robustness. We present a platform combining droplet microfluidics and magnetic 
tweezers, performing RNA purification, reverse transcription and amplification in a fully automated 
and programmable way, in droplets of 250nL directly sampled from a microtiter-plate. This platform 
decreases sample consumption about 100 fold as compared to current robotized platforms and it 
reduces human manipulations and contamination risk. The platform’s performance was first evaluated 
on cell lines, showing robust operation on RNA quantities corresponding to less than one cell, and 
then clinically validated with a cohort of 21 breast cancer samples, for the determination of their HER2 
expression status, in a blind comparison with an established routine clinical analysis.
The discoveries allowed by large-scale genomics and post-genomics have important outcomes in medicine, giv-
ing rise in particular to the development of “precision medicine”. This approach is defined by the Food and Drug 
Administration as the tailoring of medical treatment to the individual characteristics, needs and preferences of 
a patient during all stages of care, including prevention, diagnosis, treatment and follow-up1. To date, advances 
in genomic sequencing have improved the knowledge of the genetic characteristics of tumor cells and led to the 
identification of numerous new gene mutations or amplifications that may be appropriate for genomics-driven 
drug development. The panel of targeted therapies matched to specific patient’s tumor genomic alterations is fast 
increasing. As a consequence, the timely selection of the best therapy for each patient is becoming an increasingly 
difficult challenge for physicians. In parallel, important efforts are developed in clinical practice to minimize the 
invasiveness of diagnostic acts, leading, in particular, to a development of micro-biopsies and more generally to 
a reduction of the typical size of clinical samples. In order to perform assays of increasing complexity on samples 
of decreasing size, innovative technologies allowing fast and multigene screening analysis from minute sample 
material are needed2–4. We describe here such a method and validate it regarding the specific problem of HER2 
(human epidermal growth factor receptor 2) status determination in breast cancer patients.
Breast cancers represent 23% of all cancers and 14% of cancer mortality worldwide. 15~20% of breast cancer 
patients present an amplification of HER2 and subsequent overexpression in breast cancer is associated with a 
more aggressive clinical behavior5. However, adjuvant humanized monoclonal antibody directed against HER2 
(trastuzumab) or HER2-targeted tyrosine kinase inhibitors (e.g. Lapatinib) have dramatically improved survival 
of breast cancer patients with HER2 overexpression (HER2+), compared with patients without such overexpres-
sion (HER2-)6. Therefore, a reliable evaluation of HER2 expression level has become a major biomarker in daily 
clinical practice. The initial diagnosis of breast cancer and risk classification involves pretreatment core needle 
biopsies, histological diagnosis, hormone receptor and HER2 status. Recommendations for HER2 evaluation 
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methods in breast cancers are published and periodically updated by a panel of experts to improve upon the 
accuracy and convenience of HER2 testing by immunohistochemistry (IHC) or Fluorescent In Situ Hybridization 
(FISH), which represent the gold standard in clinical practice7,8. Recently, we investigated the potential of 
Quantitative Polymerase Chain Reaction (qPCR) as an alternative to FISH, in a multicentre screening based 
on 840 cases, in the framework of a prospective project entitled “Support Program for Costly Diagnostic and 
Therapeutic Innovations” supported by the French Institute of Cancer (INCa)9. As a conclusion of this study, 
qPCR represents a reliable alternative for the quantification of HER2 expression level in cancer classification. 
This technique is significantly less labor-intensive and more reliable than FISH, but it remains rather expensive, 
notably due to the cost of reagents, and as all PCR-based diagnosis approaches, it requires rigorous procedures 
and environments to avoid contamination and false-positives.
A promising technique to fulfil the fast increasing demand for throughput and multiplexing associated with 
“precision medicine”, while reducing costs, is microfluidics. This technology allows volume reduction, automation 
and confinement10. Quake et al.11 developed a Reverse Transcription (RT) -PCR assay in microfluidic devices 
based on PDMS valves, an approach now commercial available in the Fluidigm IFC device. This device allows 
outstanding single cell sensitivity and a high throughput, thanks to the parallel processing of numerous samples 
versus numerous conditions (e.g. 48 × 48). This format, in which the cost per run is essentially independent of the 
number of samples processed, yields low cost per data point at full capacity, but is not well adapted to diagnostic 
screening of gene expression, in which samples arrive at the laboratory at random times, and a short time to 
answer is required for each sample. Droplet microfluidics, which allows compartmentalization in nanoliter vol-
umes without complex integrated valves, has the potential to overcome this limit and, indeed, proof-of-concept 
experiments using droplet microfluidics were reported since then12,13. However, most droplet based approaches 
to RT-PCR so far, followed the same spirit as developed for “digital PCR”14,15, e.g. the generation and pooling of 
a large quantity of individual droplets from a single liquid sample. Higher programmability was introduced by 
electro-wetting on dielectric technology (EWOD)16 and a device performing messenger RNA (mRNA) extrac-
tion, purification and transcription has been recently described17. EWOD, however, requires complex microfabri-
cated devices with electrodes, bringing back the cost issues mentioned regarding microfabricated valves11. It also 
requires an additional upstream interface for sample and reagents loading.
Here we present a new platform aimed at bringing to the clinical world the advantages of droplet micro-
fluidics, addressing issues relevant to the specific challenges of clinical diagnosis, i.e. reliability, robustness to 
contamination, high multiplexing potential, versatility, user-friendliness, automation and cost reduction, while 
maximizing the compatibility and interoperability with currently validated and used protocols and workflows. 
The front-end of this platform is a simple motorized pipetting arm, which allows the direct sampling of samples 
and reagents from standard microtiter plates (MTP), for full compatibility with current sample storage strategies 
and equipment. As a main difference as compared to currently commercialized droplet platforms, such as those 
used in “digital PCR”, all droplets are kept equally spaced by oil in a highly confined state (a format also called 
“plug microfluidics” in literature)18,19. This way, inter-droplet contamination risk is reduced and the “identity” 
(originating well) of each droplet, built in the sequence of droplets all along the protocol, is known without need 
for internal tags. These differences alleviate several current limitations of droplet microfluidics20. The second 
original feature of the platform is the “magnetic tweezers” concept (Fig. 1), previously applied to ELISA21, and 
applied here for the first time to nucleic acids analysis. This magnetic tweezers approach allows the transfer of 
functionalized magnetic particles between subsequent droplets, bringing into the droplet microfluidics world the 
power of solid-state extraction and the flexibility of magnetic beads-based protocols. Here we use it to specifi-
cally capture and purify mRNA from a raw sample. Finally, the platform comprises a thermocycler, in which RT 
and pre-amplification PCR cycles are performed in the droplets. The whole protocol is programmed in a series 
of “trains” of confined droplets containing all the required reagents and samples. Several trains can be loaded 
sequentially and travel at constant distance from each other like in real railway. This way, multiple samples can be 
processed in a fully automated way in a single capillary, without any contact with external environment, reducing 
labour needs, risks of manipulation errors and/or contamination, in addition to a strong reduction of reagents 
and samples needs.
Different tests were performed in order to validate the platform, focusing on two genes of interest, the target 
gene HER2 and a reference gene named TBP (TATA-binding protein). As already introduced, HER2 is a major 
theranostic biomarker for breast cancer. TBP, a “house-keeping gene” with low variability of expression in breast 
cancer cells, is usually chosen in clinics as a reference in order to validate the quality of total RNA samples. A 
first series of experiments was performed with total RNA samples extracted from two human breast cancer cell 
lines: MCF7, which belongs to the luminal subgroup, has a normal expression level of HER2 and SKBR3, which 
presents an overexpression of this gene, displays a typical HER2+ status.
The ability of the platform to perform RT and PCR in droplets was evaluated and quantified. The performance 
of PCR technologies depend on many factors, including thermal control, detection, data analysis and normal-
ization, and algorithms for Cycle threshold (Ct) determination are rather complex and apparatus-dependent. 
These developments are now integrated in conventional qPCR devices in a way transparent to end-users, and 
they constitute the frame in which biologists perform their analysis and draw their conclusions. These qPCR 
platforms have a relatively high sample and reagents consumption, and integrating fluorescence detection directly 
in the droplet format could induce strong gains regarding cost and sensitivity. However, in this first study of a 
new microfluidic concept, we wanted to quantify its advantages and possible disadvantages without adding in the 
comparison other factors, such as the sensitivity and stability of a new detection scheme, the influence of which 
would combine with the microfluidic part in a way difficult to unravel. Therefore, in order to allow for a more 
reliable comparison, we chose to perform the final steps of the analysis in a conventional qPCR machine, taking 
advantage of the possibility offered by the platform to collect after processing individual samples in conventional 
microtubes or MTP.
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Then, a clinical validation of the overexpression level of HER2 in breast patient samples was performed thanks 
to a blind comparison versus the method previously established9.
Results
Design layout and characterization of the microfluidic platform. The crux of the platform is the 
magnetic tweezers technology21 (Fig. 1): a soft ferromagnetic core is positioned with its body in a tunable elec-
tric coil and its sharp tip in close contact with a capillary (Fig. 1a). The capillary is filled with fluorinated oil and 
highly confined aqueous droplets are carried over the tip by the oil flow. Applying an electric current to the coil, a 
magnetic field is generated, with a peak of about 0, 35T at the tip and a strong gradient within the capillary, able to 
attract paramagnetic beads suspended in an initial droplet traveling in the capillary (Fig. 1c). The magnetic force 
is sufficient to extract the beads as a densely packed aggregate against capillary forces and retain it immobile in 
the oil flow. The beads aggregate is kept within an aqueous subdroplet (Fig. 1d,e), so that it is never in contact with 
the oil or the channel wall. When a second droplet is carried by the flow over the tip (Fig. 1f), coalescence with the 
magnetically trapped subdroplet spontaneously occurs. If the magnetic field is turned off, the beads are released 
and dispersed inside the following droplet (Fig. 1g,h) (see Supplementary Movie 1). Thanks to this, functional-
ized beads can be used to extract analytes of interest from a complex sample and carry them between different 
media, with very little carryover of the initial matrix. The procedure can be repeated using series of tweezers so 
that particles can be sequentially exchanged from one droplet to the other within a droplet train. For the present 
RT-PCR protocol, the sequence of drops is described in Fig. 1. The first droplet contains oligo-dT magnetic beads 
in suspension in their storage buffer. They are extracted and released in a second droplet containing the sample 
of total RNA (Fig. 1j–l); here mRNA is captured on the magnetic beads by hybridization (Fig. 1m). The magnetic 
beads are captured by a second tweezers after 5 minutes of incubation (set by the distance between tweezers and 
by the flow velocity), allowing the extraction of the mRNA. The cluster is then washed by a washing buffer droplet 
(Fig. 1n) and finally redispersed in a last droplet containing the RT-PCR mix (Fig. 1o). The whole train is then 
transported seamlessly to a serpentine channel in a heated element, where RT and PCR will be performed. In 
order to achieve full automation, a dedicated program using LabView 2011 (National Instruments) was developed 
to synchronize magnetic field actuation with the passage of the droplets (see Methods and Supplementary Note 1).
Droplets trains are generated by pipetting the different solutions directly from a MTP. The use of confined 
droplets, which can travel over long distances keeping their initial order and spacing22, allows to implement in 
a flexible way complex protocols, built in the sequence of droplets. This leaves a lot of flexibility for program-
ming, since the order and content of droplets can be customized at will by the end-user, including the possibil-
ity to program different protocols into successive trains. The platform, schemed in Fig. 2, is inspired from the 
work of Chabert et al.23, with some differences aimed at accounting for the specificities of RT and at increasing 
Figure 1. Magnetic tweezers technology and experimental workflow for RT-PCR experiment. (a) Picture of 
the magnetic tweezers with the capillary (highlighted with a red liquid). A second passive magnetic tip, placed 
opposite to the first with regards to the capillary, contributes to field lines shaping and to the optimization of 
the magnetic force21. (b–h) Sequence of images showing the extraction and the redispersion of magnetic beads 
from one droplet to another one (colored in orange), switching ON and OFF the electric current in the coil.  
(i) Scheme of a typical train of droplets used for the RT-qPCR analysis: 1) oligo-dT magnetic beads, 2) total 
RNA sample, 3) washing buffer and 4) RT-PCR mix. (j–o) Workflow of beads and droplets manipulation during 
the protocol.
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interoperability with current diagnosis platforms. The system involves a high-precision syringe pump (Syringe 
1) dedicated to droplets sampling, a high volume syringe pump (Syringe 2) to push trains of droplets at con-
stant velocity (set at 0.1 μ l/s) through the device, and a compact 1-arm motorized pipettor allowing programmed 
sampling from any well in a MTP. Sampling is performed by sequential aspiration of sample or reagents and oil. 
PDMS microfluidic devices (Fig. 2c,d) are designed to operate as switching and storage junctions in order to 
create two independent fluidic circuits. Using those and a combination of pinch valves (Fig. 2b), the system is 
able to generate a train of droplets, while previously generated trains are flowing in the rest of the platform (see 
Methods). This approach allows a continuous operation, wherein an intermittent pipetting process generates 
successive trains, while previously generated trains are processed at constant speed. It also allows “on-the-flight” 
reprogramming, i.e. varying the samples and reagents combination for next trains, while a previously prepared 
train is studied, without interrupting operation.
In order to avoid any contaminations between different wells by the capillary, the same PTFE capillary was 
used for sampling and droplets train transport. The carrier oil was fluorinated oil (FC-40, by 3 M) containing 
a fluorinated surfactant (2% of 1H, 1H, 2H, 2H-perfluoro-1-decanol, by Fluorochem). In such conditions, the 
surface tension between the oil and the PTFE is low enough to guarantee that a small film of FC-40 is always 
present at the end of the capillary. Fluorinated oil also reduces the risk of molecules diffusion from the aqueous 
phase droplet into the continuous oil phase, avoiding cross-contamination problems24. This has been demon-
strated performing systematically negative control tests, consisting in normal train of droplets where the RNA 
droplet is replaced by washing buffer, interspaced between positive trains. In particular, a negative control train 
was systematically included every 7 positive trains and all trains of droplets were treated using the same protocol, 
from the droplet generation to the qPCR amplification. In all the tests (total of more than 200 for the whole series 
of experiments presented in this work), the qPCR curves from the negative control droplets did not shown any 
amplification. An example of this can be observed in Supplementary Fig. 2, which shows raw data obtained of the 
amplification curves. In contrast with conventional droplet microfluidics, in which surfactants are designed to 
Figure 2. Microfluidic platform for the generation of trains of droplets. (a) Scheme of the droplet 
microfluidic generator module, which combines a MTP plate placed under a motorized pipettor arm (Cetoni), 
two syringes, two pinch valves (b) and two PDMS chips (c,d). The connections between the PDMS chips 
inlets and the different parts of the platform are numbered from 1 to 6 and the same numbers are reported 
on the scheme (a). Syringe 1 is connected with inlet 1 of PDMS chip 1 (Fig. 2c) while syringe 2 is connected 
with PDMS chip 2 (Fig. 2d) at inlet 5; inlets 2 and 3 are connected respectively to the pipettor head and to the 
PDMS device 2 (inlet 4), thanks to tubing passing through the two valves (V1 and V2). Finally, inlet 6 of the 
second PDMS chip is connected with the capillary in which droplets are driven between the magnetic tweezers. 
In order to generate droplets trains, while other droplets are flowing in the rest of the platform, homemade 
software switches alternatively between two conditions represented by red and blue lines. In condition 1, V1 
is open and V2 is closed; syringe 1 is in aspiration mode generating and storing droplets in the PDMS device 
1 while syringe 2 is pushing oil in the rest of the circuit. Then, in condition 2 (V1 closed, V2 open), syringe 
2 is stopped and syringe 1 pushes the generated droplet train over PDMS device 2; after that, condition 1 
is reactivated, and a new droplet train can be generated while the previous one is flowing in the processing 
system. In order to avoid pinching of a droplet by a valve, 10 mm oil spacers were introduced between droplet 
trains, and pipetting and valving were synchronized to ensure that valves close only onto these spacers. Each 
train in the series of trains can be prepared from any arbitrary combination of samples and reagents. The water 
and oil phase solutions are placed in the MTP, which is covered by a mineral oil film of 2–3 mm for avoiding 
contaminations or solution evaporations. The length of the scale bar of (b–d) is 1 cm.
www.nature.com/scientificreports/
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prevent droplet merging by maximizing steric repulsion between the surfactant molecules25, we used here per-
fluorodecanol, which produces stable water phase droplets in fluorinated oil and prevents wall contamination, but 
still allows the merging of droplets and subdroplets upon contact in a highly confined state26.
In order to prevent evaporation problems27 and to insulate the RNA samples from the external environment, 
reducing risks of cross-contamination and degradation by ambient RNases , a layer of mineral oil is dispensed over 
the MTP after having placed the solutions. In contrast with previous work23, mineral oil was preferred to fluori-
nated oil: being less dense (0.838 g/mL at 25 °C) than both water (about 1 g/mL at 25 °C) and FC-40 (1.855 g/mL 
at 25 °C), it stays on top of them during pipetting (Fig. 2a), without requiring the use of specific MTPs. Overall, 
the droplet size dispersion ranged between 1–2% for droplet volumes between 50–350 nL. During the experimen-
tal workflow droplets of 250 nL were used.
After the steps performed in the magnetic tweezers, droplets containing the purified mRNA mixed with 
reverse transcriptase, polymerase and primers are flown into a temperature controlled module kept at 50 °C for 
5 minutes (see Supplementary Fig. 1) and the RT step is performed in the droplets. In order to evaluate the plat-
form’s automation capability and robustness, 45 trains of droplets were continuously generated and processed 
without human intervention in the same experiments. They allowed analyzing two genes of interest from 7 total 
RNA samples and three negative controls performed in triplicate. The whole automated protocol, from droplets 
generation to the RT, takes about 4 hours. After that, in a first series of experiments, droplets containing the 
complementary DNA (cDNA) were collected in standard PCR tubes, pre-loaded with TaqMan mix, to perform 
the qPCR in a conventional instrument (SmartCycler, by Cepheid). In a second protocol, aimed at demonstrat-
ing the possibility to perform RT-PCR seamlessly in the platform, the droplets were subjected to a series of 15 
pre-amplification by thermal cycling, before transfer to the conventional qPCR machine.
Optimization and validation of the microfluidic platform with cell lines. Calibration curves for 
TBP and HER2. A first series of experiments was performed to check that the high surface to volume ratio 
intrinsic to microfluidics does not affect the efficiency of the reaction, e.g. by enzymes adsorption or loss. This 
was achieved by varying enzymes concentration in the RT-PCR mix (Supplementary Table 1). Increasing the con-
centration beyond that suggested by the supplier did not yield any decrease of Ct, whereas decrease of enzymes 
concentration yielded an increase in Ct only for concentrations below 20% of the standard one. This demonstrates 
that the concentration recommended by the supplier in macroscopic format also corresponds to a robust opti-
mum of efficiency in our platform, so this concentration was used in following experiments.
Then, the capture efficiency of mRNA by the magnetic beads was evaluated by performing sequential capture 
steps from the same initial sample (see Supplementary Note 2 for details). Parallel tests performed by the droplet 
microfluidic platform and in conventional PCR tube, using the same protocols, show in both cases an excellent 
capture efficiency of 95 ± 2% for the droplet format and 93 ± 2% for the batch mode. The similarity of the effi-
ciency in both modes demonstrates that the microfluidic format indeed exploits the good capture efficiency of the 
beads used here to its best extent, and does not yield any specific loss.
The purification efficiency (defined here as the rejection factor for non-messenger RNA) was evaluated by 
quantifying the total RNA content of the purified droplet and the waste droplet, respectively, and was shown to be 
better than 100X (see Supplementary Note3 for more details).
Calibration curves for TBP and HER2 genes were then prepared with total RNA quantities ranging from 
1.5 ng/drop to 15 pg/drop, corresponding to 6 ng/μ l to 60 pg/μ l; this range is lower than the typical concentrations 
used for the routine quality check for clinical samples (6 and 25 ng per assay). The lowest calibration point, about 
15 pg, roughly corresponds to the total mRNA content of a single cell or, considering the typical expression level 
of HER2 in breast cancer lines, between 10 and 1000 copies of target mRNA per droplet. Figure 3a,b show the 
results obtained for MCF7 and SKBR3 cell lines, respectively. Each curve is the average of a triplicate of the same 
experiment repeated three times, starting from the same MTP. An example of raw data obtained is provided in 
Supplementary Fig. 2. The Cts horizontal error bars for the RNA/droplet concentrations are evaluated by the 
propagation of error on the droplet volume, while the verticals error bars are given by the standard deviation of 
the triplicate (CV < 1%). Thus, the error bars in Fig. 3 represent the variations due to our new setup and protocol, 
avoiding possible external sources of error such as degradation of the RNA sample or inaccuracies of MTP prepa-
ration. This point will be fundamental for the clinical validation, in which a sample calibrator has to be analyzed 
at the same time and with the same protocol as the patient samples. Calibration curves in Fig. 3 are linear in the 
investigated range (R2 > 0.96), demonstrating that the efficiency of mRNA capture and of the RT reaction per-
formed in droplets are not influenced by the initial quantity of mRNA. The efficiencies (Eff) of the qPCR, derived 
by the curves’ slope reported in the graphs, are always higher than 97%. As expected, the Cts obtained for TBP do 
not differ significantly between the two cell lines. For HER2, in contrast, SKBR3 shows Cts about 5units smaller 
than those of MCF7, in line with the HER2+ and HER2- status of these cell lines.
It is also worth noting that these results confirm the absence of contamination between droplets, already 
demonstrated by negative controls presented in the first part of the results section, above. All data were derived 
from different trains of droplets performed in the same capillary, and comprising initial RNA concentrations 
over two orders of magnitude of concentration. In particular, in some cases, the train at lowest concentration 
are generated directly followed a train at the highest concentration. If some cross-contamination occurred the 
measured Ct should have a larger dispersion at low RNA concentrations than at high, disrupting the linearity of 
the calibration curves.
Finally, the possibility to perform RT-qPCR in a single step in the droplet was evaluated by an additional series 
of experiments performed on total RNA from MCF7 in which, after RT, the droplets trains are arrested in the 
temperature unit, and subject to PCR. Ct values in PCR depend to some extent on the apparatus and sensitivity 
of the detection so, in order to allow for a more quantitative validation, we chose a hybrid method in which 15 
temperature cycles are performed in the capillary and the droplets are then transferred to the SmartCycler for 
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final qPCR analysis. The results (Fig. 3c) show that, within experimental error, the calibration curves obtained 
are shifted by 15 Cts as compared to the previous ones, indicating that the efficiency of the PCR is similar in the 
droplets and in the conventional thermocycler. Moreover, the slopes of the graphs with and without 15 cycles of 
pre-amplification are also comparable, suggesting that no additional loss or degradation of enzymes occurred 
during thermal cycling in the droplet, and that the in-drop amplification provided DNA fragments of a similar 
quality as those obtained in the SmartCycler. Combined together, these results demonstrate that RT-qPCR can 
be performed in the highly confined droplets of the platform, without loss of reproducibility, quality and perfor-
mance and without inter-trains contamination.
Clinical Validation with breast cancer patient samples. Clinical validation was performed in a blind 
protocol, using 21 samples of total RNA extracted from percutaneous biopsies of breast cancer patients of 
Saint-Louis Hospital in Paris (France). The samples were analyzed, independently and in parallel, by classical 
RT-qPCR at the hospital (see Methods) and by the droplet microfluidics platform, using the SmartCycler as 
end-line quantitative analyzer, as described above for cell lines. The total RNA quantities used for this validation 
were, respectively, 20 ng per test for the Hospital, and 250 pg per test (or 250 pg/droplet) for the microfluidic plat-
form. All results were analyzed with the 2−ΔΔCt Method28,29, which is well established for RT-qPCR. This strategy 
allows the normalization of the expression of the gene of clinical interest (HER2) to a reference having a stable 
expression level between individuals (in our case TBP) and also with a reference sample without HER2 overex-
pression (MCF7 cell lines for the droplet platform and a pre-defined set of samples for the hospital platform). This 
allows to take into account possible differences of RNA or DNA quality and/or amplification between the two 
genes. The result of this analysis is the Fold difference Fd, which quantifies the difference in expression between 
the patient sample and the control sample: ideally, Fd ≈ 1 would mean no overexpression and the higher is Fd, the 
higher is the expression of the gene. In practice, however, there is no absolute reference of what is a “normal” 
expression, both for HER2 and TBP, and measured expression levels depend to some extent on the details of the 
experimental procedure, so the Fd threshold of positivity has to be evaluated on a heuristic basis, for a given plat-
form. In the diagnostic laboratory at Saint-Louis Hospital, the Fdcut-off ratio to consider a sample HER2 negative 
or positive was determined on a tumor training set using univariate partition method (XLSTAT software) and 
correlation with IHC–HER2 expression. Final result were expressed as a normalized ratio considered as 
over-expressed if Fd >79,30. The two sets of data with the Ct and Fd values are reported in the blue and yellow 
columns of Supplementary Table 2. Fd values obtained on the droplet platform are systematically higher than 
Figure 3. qPCR calibration curves. Calibration curves for (a) MCF7 and (b) SKBR3 cell lines for genes HER2 
and TBP, represented in blue and green, respectively. Cts are plotted in logarithmic scale as a function of the 
total RNA concentration. The qPCR efficiency Eff, reported below the fit parameters, was extracted from the 
slope of the linear fits. (c) Calibration curves for MCF7 without (blue and green points and fits) and with (red 
and black points and fits) 15 PCR pre-amplifications cycles: as expected, the curves are shifted of about 15 Cts. 
Error bars are not visible when they are smaller than the point.
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those obtained at the hospital. Such a discrepancy could be expected considering the relative nature of this param-
eter and our use of a different reference in the two environments. This complication can be overcome by a corre-
lation analysis, as previously proposed31. The linear correlation between the two sets of data yields a Pearson 
Correlation Coefficient 0.84, showing good correlation. Most importantly regarding diagnosis, the correlation 
graph (Fig. 4) between the droplet and hospital platforms shows an identical segregation of positive and negative 
patients, plotted in red and black, respectively. By definition, data from the hospital segregate in two data sets on 
each side of the ≅Fd 7threshold. More specifically, in this cohort, the highest Fd of negative patients is at 1.19 
and the lowest positive is at 11.71 (green dash line). All data obtained on the microfluidic platform segregate 
together with the data from the hospital, the highest negative being at 10.48, and the lowest positive at 39.67 (blue 
dashed lines).
Discussion and Conclusions
We presented a novel droplet microfluidics platform for gene expression quantification by RT-qPCR. As already 
introduced above, the progress of “precision medicine”, in which an increasing number of molecular biomarkers 
must be tested on the same patient sample, is limited by conventional techniques, in which large quantities of 
samples and reagents are requested for every single assay. Additionally, gene expression information is carried 
by mRNA, which only represents 1–3% of the total RNA and is a more fragile and delicate nucleic acid than 
DNA. Finally, even minimal contamination by post-PCR amplification products from other reactions could easily 
yield false positives. To overcome these difficulties, very strict, time consuming and space-intensive workflows 
are required. These requirements, together with the cost of reagents, constitute a hindrance to the spreading of 
precision medicine approaches in less-favored settings and a cost burden on the health system in more favored 
countries.
The microfluidic platform developed here provides a path overcoming these limitations, while remaining 
compatible with the standard equipment and sample storage available in diagnostic laboratories. Starting from 
total RNA samples distributed in conventional microtiter plates, this droplet platform permits the generation of 
different trains of droplets allowing mRNA extraction by magnetic beads, washing, redispersion in RT-PCR mix 
and finally the thermal steps for RT or RT plus pre-amplification cycles of PCR, all in droplet format. Various 
combinations of samples and RT-PCR mixes can be programmed dynamically from the same set of samples and 
reagents.
The platform was first validated using total RNA extracted from MCF7 and SKBR3 cell lines. Calibration 
curves for both TBP and HER2 genes expression levels were found linear between 1, 5 ng and 15 pg of total RNA 
per droplet. As mentioned above, it is worth noting that the smallest concentration of total RNA used in this 
series is comparable with the RNA concentration of a single cell (about 20 pg). Therefore, although not relevant 
to the present clinical application and validation, our platform is suitable to perform RT-qPCR from single cells. 
Since technologies for single cell encapsulation in droplet exist13,32, this could open the route to a strong simplifi-
cation of single cell expression studies.
During these tests, as expected, MCF7 and SKBR3 cell lines showed normal and overexpressed HER2 gene 
level, respectively, and the same level of TBP expression. Additionally, the curves were found parallel, yield-
ing PCR efficiencies between 97–99%, allowing their relative expression analysis. When 15 cycles of PCR 
Figure 4. Correlation between hospital and microfluidic platform results. Graph in Logarithm scale (base 2) 
of the Fd obtained by the Saint-Louis Hospital platform versus the Fd obtained by the droplet microfluidic 
platform. Samples disclosed a posteriori as HER2- samples are plotted in red, and HER2+ ones in black. The 
dashed lines help to identify the excluded zone between the two populations: blue for the droplet platform 
(10.48–39.67), green for the hospital (1.5–11.71).
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pre-amplification are performed in the droplet following RT, a shift of 15 cycles in the calibration curves is 
obtained, showing that the platform allows inline mRNA purification, reverse transcription and DNA amplifica-
tion with an efficiency comparable to that observed in conventional PCR machines. To date, in the routine anal-
ysis developed at Saint-Louis Hospital, total RNA is used to minimize manipulations and risks of contamination. 
Indeed, mRNA purification is not mandatory for all applications and is often avoided in conventional protocols. 
In our platform, however, this step can be included without additional sample manipulation or risk of contam-
ination, since it is performed entirely in the microfluidic capillary. Implementing this additional purification is 
thus a way to increase the robustness of the method, by getting rid of a large majority of spurious RNA, at no 
additional risk and with negligible increase in the whole process time. Additionally, it is interesting to note that 
new technologies such as RNA sequencing, require highly purified samples to perform multiplex reactions and 
tend to use more and more often additional magnetic beads-based purification steps to avoid any non-specific 
reactions33. Therefore, we believe that our platform, performing in “native” mode mRNA extraction by magnetic 
beads, Reverse Transcription and PCR pre-amplification, will also make it an interesting front-end technique for 
these new massively parallel technologies34,35.
A blind test versus an established routine clinical diagnosis was then performed on a cohort of 21 patients for 
the determination of HER2 amplification status, using the 2−ΔΔCt Method, typical for qPCR analysis. The results 
show a good quantitative correlation of 0.84 between the Fd values. Moreover, in Fig. 4 the two populations of 
normal and overexpressed HER2 tumors are well identified, demonstrating that all the 21 patient samples studied 
were well characterized by the microfluidic platform in the blind test.
The platform used here allowed the processing of one sample every 3 minutes, i.e. about 500 samples per 
day. This is quite sufficient for most clinical diagnosis expression needs. Indeed, in research, experiments can 
be pooled and synchronized, in order to take advantage of devices processing in parallel many samples, but in 
clinical diagnosis, the ability to provide a fast response for each patient at a low cost is often as important or more 
important than theoretical throughput. Strategies involving parallel processing in disposable chips are thus poorly 
adapted, since the operation cost per chip is essentially independent of the number of samples processed in the 
chip, so that samples must be pooled up the full capacity of the chip or close to it, before processing to keep costs 
low. Our system, in contrast, does not use disposable chips, samples are processed sequentially and reagents are 
well protected under oil in the machine and can be kept for re-use on-demand. Therefore, the typical one hour 
response time can be maintained without significant cost increase from a single sample per day to the maximum 
rate of 500 samples per day, making the platform particularly suitable and cost-efficient for situations in which the 
number of samples to treat per day can vary widely, typically from a few to several hundred. It should be noted, 
however, that in order to best fulfill clinical requirements, the machine used here was aimed at flexibility but not 
optimized for speed. For higher throughput applications, the use of a more industrial pipetting stage, for instance, 
could allow the parallelization of the droplet generation step. Additionally, both valves and magnetic tweezers 
used here could accommodate more capillaries with little modification, so the throughput of the system could be 
increased by one or two order of magnitudes without major modifications.
The presented microfluidic platform shares with previous droplet microfluidic systems the use of oil to com-
partmentalize aqueous media in multiple nanoliter scale microreactors and thus, the possibility to considerably 
reduce reagents and sample consumption but, besides this, it has very different aims. Current droplet microfluidic 
systems use high-throughput generation of droplets from one or a few streams, to achieve thousands to millions 
of independent reactions in discretized samples of the same mix. This has opened, for instance, the route to 
digital “one molecule per droplet” approaches, leading to spectacular increases in sensitivity in PCR14, but the 
cost of analysis per sample remains high. Here, in contrast, we use compartmentalization to increase automation 
and reduce volume, but remain in the “one reaction per sample” paradigm. In other words, a combination of a 
single droplet of sample and a single droplet of PCR mix is sufficient for typing the sample regarding to the cor-
responding sequence. As consequence, sample and reagents consumptions are directly commensurate with the 
volume ratio between a single droplet and a MTP well. This, combined with the magnetic tweezers permitting 
droplet-to-droplet extraction, purification and transfer, allows the implementation of essentially any protocol 
currently implemented in pipetting robots. For instance, in this study, starting from the same liquid samples, 
we easily introduced in our protocols triplicates assays and negative control tests, which are fundamental in 
diagnostic analyses. The microfluidic platform also shares with current robotized platforms MTPs as common 
entry and exit points, allowing easy evolution from existing workflows. However, it presents several advantages 
as compared to conventional robots, which remain in the MTP format through the whole protocol; at first, the 
reduction of the sample volume and RT reagents needed to obtain a data point is reduced by a factor between 40 
and 200. Even smaller volumes could be sampled with syringes of smaller diameters, but we did not consider this 
useful here, since a X40 volume reduction, in combination with the absence of microfabricated disposables, and 
a strong reduction in plastic consumables, are already sufficient to decrease consumables cost to a level negligible 
as compared to other costs in the workflow, such as blood sampling and labor. Additionally, any sample contained 
in a single well (typically 20 to 100 μ l) can be typed versus up to 100 PCR mixes contained in different wells or, 
alternately, a single PCR mix of 20 to 100 μ l can be used to screen up to 100 samples, in a fully programmable 
manner and in any combination of samples versus mixes. This opens the route to multi-biomarkers screening 
from the same sample volume, to costs reductions and to the implementation of diagnostic sequences based on 
decision trees, without additional manipulation; for instance, a new train of droplets can be prepared from the 
same sample well with different primers, following the result of a first test, in an operator-decided or automated 
way. Another advantage is a reduction of risks of human error or contamination, either by RNase (sample deg-
radation) or by DNA (false positives), thanks to the fact that operations are performed under oil all along the 
protocol. Indeed, the droplet platform was installed in a multi-purpose biochemistry lab, in which various other 
experiments involving amplification of human DNA were also performed, without pre-PCR and post-PCR seg-
regation, and no event suggestive of contamination was observed during the whole study. This contamination 
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control advantage works both ways, i.e. it can also increase the protection of users, for the manipulation of poten-
tially infectious samples.
Finally, the microfluidic platform is very versatile regarding protocol development: it can implement in a fully 
automated manner most existing protocols involving magnetic beads and use existing kits, except for a widely 
reduced reagents consumption, having an important impact on reagents cost. In the experiments presented here, 
this advantage is somewhat reduced by the final step, performed in a conventional thermocycler for the sake 
of clinical comparison. This step still requires the same quantity of polymerases and primers than in conven-
tional methods. However, we have demonstrated that RT and qPCR can be performed in the same droplet. This 
opens the route to the development of a next generation device, comprising on-chip fluorescent detection, as 
already demonstrated in several proof-of concept experiments36–38. This improvement has the potential to further 
increase sensitivity, since it will avoid the dilution performed during droplet collection, in the present protocol, 
and also reduce the consumption of PCR reagents. Thus, either in the form presented here, as a front-end device 
for the preparation of direct or pre-amplified cDNA, or as a fully integrated device including detection, we believe 
that the droplet microfluidics and magnetic tweezers technology presented here will bring considerable gain in 
cost, robustness and simplicity of operation for a multiplicity of nucleic acid analysis applications, in particular 
in diagnosis.
Methods
Droplet microfluidic platform description:. The flow control part of the platform is designed to generate 
a train of droplets by sequential pipetting, while other droplets already generated are processed at constant and 
controlled speed in the rest of the platform. The platform comprises two syringe pumps (Nemesys, by Cetoni 
GmbH) equipped with 250 μ L and 2, 5 mL syringes (by SGE), a motorized pipettor arm (Rotaxys, by Cetoni 
GmbH), two pinch valves (by NResearch Inc.) that are alternatively open and closed. Two PDMS devices are used 
for capillary connections (see Fig. 2). A 384-wells MTP is used for reagents and samples storage. A volume of 
25 μ L of each solution is distributed in individual wells placed below the motorized pipetting arm. Mineral light 
oil (by Sigma-Aldrich) is then spread on the plate in order to avoid reagents evaporation. The MTP is placed on 
a home-made holder that can be moved in X, Y, Z directions by a manual stage (Thorlabs). Once the pipetting 
capillary is aligned with the reference well, software controlling the motion of the pipettor’s arm and the syringe 
is operated. Capillary is moved from one well to the other, pipetting in each one the desired volume of liquid 
and inserting between each water droplet a fluorinated oil plug. Considering the volume capacity of a single well 
and the volume of the droplet and oil phases, it is possible to generate from a single solution of 25 μ l about 100 
droplets of 250 nl.
Figure 2 schematically describes how the different parts of the platform are connected and how the platform 
allows droplet generation while the previous trains are flowing in the processing system. The pipetting takes 
about 1 second per droplet. Including the time needed for arm motion and oil pipetting, one train of droplets 
can be generated and manipulated between the valves and the PDMS devices in about 2–3 minutes. The PDMS 
connectors were prepared by standard double replica molding techniques, starting from a brass mold made by 
micro milling (see Supplementary Fig. 3). The pinch valves used operate by clamping an elastic capillary by a tip 
controlled by an electromagnet (see Fig. 2b). PTFE capillaries used for droplet manipulation cannot be used for 
this purpose due to their poor elastic proprieties. Therefore, in the valves they were replaced by a silicone capil-
lary having the same internal size than the PTFE one (0.31/0.64 mm ID/OD, by Helix Medical). The connection 
between the two different capillaries was achieved using a third silicon capillary (ID = 0.50 mm, OD = 1.3 mm, 
by Deutsch & Neumann). To ensure good wettability by fluorinated oil, PDMS devices and silicone capillaries 
were treated with a solution of (Tridecafluoro-1, 1, 2, 2-tetrahydrooctyl)trichlorosilane in FC-40 (5% w/w) for 1 h.
When leaving PDMS connector 2, droplets are driven in a single seamless capillary between i) the two mag-
netic tweezers made of two magnetic coils (copper wire of 71 cm and 1 mm diameter, by Radiospares) surround-
ing soft ferromagnetic tips (AFK502 alloy, by Aperam) and ii) the thermocycler provided by Prime Techne and 
further adapted. Two Macro Objective (MLH-10X) mounted on two low cost CMOS Cameras (acA1300–60 gm, 
by Basler) and white LED back light illumination (by Schott Lighting and Imaging) were used for droplet obser-
vation and image analysis for magnetic tweezers control (see Supplementary Note 1). The cameras are connected 
to the computer by the NI PCIe-8236 card (National Instruments) and the communication between the home 
made LabVIEW software and the magnetic coils is achieved by the NI USB-6525 interface (National Instrument). 
Since the droplet generator and the magnetic tweezers modules can work at the same time, after preparation 
of the samples and reagents MTP, any combination of samples and reagents can be processed in any order and 
numbers of iterations, until exhaustion of the volume (about 500 analyses per sample for an initial load of 100 μ l).
Samples. Cell lines. Human breast cancer cell lines SKBR3 (HER2-like phenotype) and MCF7 (luminal 
phenotype) were acquired from ATCC. They were cultured in DMEM culture medium supplemented with 10% 
FBS and 2% glutamine without antibiotics. They were harvested every week to amplify enough material for one 
year use of controls.
Patient cohort samples. The retrospective study was conducted on 21 breast cancer pre-treatment core-needle 
biopsies. Paraffin-embedded sections of AFA-fixed biopsies, used for the histological diagnosis were assessed 
by immunohistochemistry (for estrogen receptor ER), progesterone receptor (PR) and HER2 content. Tumours 
were considered “HER2-positive” if more than 30% of cells showed definite membrane staining. Control by FISH 
or SISH or qPCR was done for ambiguous cases. Frozen samples were used for the present study. They were 
processed under RNAse-free conditions. They represent a part of a more extensive protocol analysing diagnosis 
markers (ER, PR and HER2) and proliferation markers. The protocol and the ancillary studies were reviewed and 
approved by an ethics committee (CPP Ile de France IV, France, n°2013/27NICB, 30/07/2013).
www.nature.com/scientificreports/
1 0Scientific RepoRts | 6:25540 | DOI: 10.1038/srep25540
Total RNA extraction. Cell lines and tumors’ nucleic acids were extracted by phenol/chloroform proce-
dure39 and qualified and quantified using Bioanalyzer (by Agilent Technologies) and Nanodrop 2000 instruments, 
respectively. Tumor cell purity and presence of in situ carcinoma were assessed on adjacent tumor H&E-stained 
sections, by the referent pathologist30.
2−ΔΔCt Method for folding difference (Fd) evaluation. The 2−ΔΔCt Method28,29 was used for the evalu-
ation of the folding difference values starting from the Cts obtained by the droplets platform and the conventional 
hospital protocols. It proceeds as follows: at first, the Δ Ct is defined as the difference in Ct between the gene of 
interest (HER2) and the reference gene (TBP), both for the sample and for the reference:
∆ = −Ct Ct HER Ct TBP( 2) ( ) (1)sample sample sample
∆ = −_ _ _Ct Ct HER Ct TBP( 2) ( ) (2)ref sample ref sample ref sample
where “ref_sample” represents the normal control sample. Then, Δ Δ Ct is calculated as the difference between 
the two Δ Ct:
∆∆ = ∆ − ∆ _Ct Ct Ct (3)sample ref sample
finally, the Fold difference (Fd) value is calculated with the following equation:
= .−∆∆Fd 2 (4)Ct
Quantification of HER2 overexpression RT-qPCR – hospital protocol. First-strand cDNA synthesis 
was performed with 1 μ g total RNA using Superscript II Reverse Transcriptase (Invitrogen Corporation) in a final 
volume of 25 μ L. Quantitative PCR were performed on LightCycler 2.1 instrument (Roche Diagnostics). HER2 
overexpression was evaluated by relative quantification using TATA-binding protein as endogen control (TBP) 
using 20 ng cDNA as previously described30. A 5 μ L diluted sample of cDNA (20 ng) was added to 20 μ L of the 
PCR mix. The thermal cycling conditions comprised an initial denaturation step at 95 °C for 10 min, 45 cycles at 
95 °C for 15 sec, and annealing temperature, 60 °C for 1 min.
Final result were expressed as a normalized ratio Fd considered as over-expressed if Fd > 7. The cut-off ratio 
was determined on a tumors training set using univariate partition method (XLSTAT software) and correlation 
with IHC–HER2 expression as previously published by our group30.
Preparation of the solutions for RT-qPCR performed in the droplet platform. Before transferring 
into micro titer plate, total RNA, stored at −80 °C, was quantified & qualified using Nanodrop&BioAnalyzer 
(Agilent) instruments. Desired total RNA quantities were diluted into Binding Buffer provided with the 
DynabeadsOligo(dT)25 Kit (61002, Life Technologies) and BSA (B14, Thermo Scientific) was added to a final 
concentration of 0.4%. For the preparation of the paramagnetic beads solutions for droplet generation, after 
resuspending Dynabeads in the vial, 100 μ L was transfer to a tube and placed in a magnet for 1 min. The super-
natant was discarded and Dynabeads were resuspended into 100 μ L of Binding Buffer, well mixed and placed in a 
magnet for 1 min. The supernatant was discarded and Dynabeads were resuspended into a 25 μ L mix composed 
of 23.5 μ L Binding Buffer, 0.5 μ L 20% BSA, 1 μ L SUPERase In™ RNase Inhibitor (AM2694, Life Technologies). 
Two 1.5 ml tubes containing a 50 μ L Washing Mix (48 μ L Wash Solution, 1 μ L 20% BSA, 1 μ L RNase inhibi-
tor) were prepared. CellsDirect™ One-Step qRT-PCR kits (11732, Life Technologies) was used to prepare the 
Reverse transcription mix as follow: 12.5 μ L of 2X Reaction Mix, 1 μ L of anchored Oligo(dT)23VN (S1327S, 
NEB), 1 μ L of each Forward and Reverse primers (custom primers to study HER2 or TBP or Actin b from IDT), 
1 μ L of SuperScript® III RT/Platinum® Taq Mix with RNaseOUT™ Ribonuclease Inhibitor and qsp to 25 μ L with 
DEPC-treated water. Each solution was well mixed by pipetting before transferred into 384-well titer Plate.
After the microfluidic process (mRNA capture, washing, Reverse transcription), droplets containing cDNA 
were recovered into 1.5 mL tubes with 5 μ L of DEPC-treated water. qPCR reactions were performed in the 
SmartCycler instrument (by Cepheid), with a mix composed of: 12.5 μ L of 2X Reaction Mix, 1 μ L of each Forward 
and Reverse primers (custom primers to study HER2 or TBP or Actin b from IDT), 0.5 μ L of TaqMan™ Probe 
(custom probes to study HER2 or TBP or Actin b from IDT) 1 μ L of SuperScript® III RT/Platinum® Taq Mix 
with RNaseOUT™ Ribonuclease Inhibitor, 5 μ L of cDNA output and qsp to 25 μ L with DEPC-treated water. The 
thermocycling program was: an enzyme activation step at 95 °C for 120 sec, followed by 50 cycles of 95 °C/15 sec 
and 60 °C/30 sec.
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